# CGM Use in Adults With Type 2 Diabetes on Basal Insulin

Study · id `cardio:ct-nct05944432` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05944432](<https://clinicaltrials.gov/study/NCT05944432>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05944432

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 469 participants.

## Technical summary

Registry record NCT05944432. Randomized; no masking; primary purpose treatment. Start 2023-07-26 (actual); primary completion 2026-02-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 469 participants (enrolled count; ClinicalTrials.gov record NCT05944432, source copy `cardio:ctgov-nct05944432-2026-10-13`, retrieved 2026-10-26)
- Started: 2023-07-26 (actual) (ClinicalTrials.gov record NCT05944432, source copy `cardio:ctgov-nct05944432-2026-10-13`, retrieved 2026-10-26)
- Primary completion: 2026-02-19 (actual) (ClinicalTrials.gov record NCT05944432, source copy `cardio:ctgov-nct05944432-2026-10-13`, retrieved 2026-10-26)
- Completion: 2027-11-30 (anticipated) (ClinicalTrials.gov record NCT05944432, source copy `cardio:ctgov-nct05944432-2026-10-13`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT05944432, source copy `cardio:ctgov-nct05944432-2026-10-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05944432-2026-10-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: CGM Use in Adults With Type 2 Diabetes on Basal Insulin
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): FreeStyle Libre 3 Continuous Glucose Monitoring System.
- Intervention (Device): Self monitoring of blood glucose
- Lead sponsor: Abbott Diabetes Care
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Abbott Diabetes Care (`cardio:org-abbott-diabetes-care`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial (`cardio:pubmed-42035781`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 295c76586de3c1882938e3f59253c2c92d0a18678c736ab6edf36e12b8852f3b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
